Reveal all classes of structural variants using Bionano’s optical genome mapping Stratys™ System. Explore the Stratysphere!

Unparalleled Detection of Chromosomal Aberrations in a Single Workflow

Detecting broken, missing, rearranged, or extra chromosomes provides critical, actionable insights for cancer and genetic diseases, yet traditional cytogenetic methods fall short of discovering key chromosomal aberrations.

Fundamental issues with classical cytogenetic approaches

Karyotyping

  • Poor resolution (5-10Mb or lower for hematological malignancy samples)
  • Laborious and time consuming
  • Requires cell culture
  • Subjective analysis
  • Overlooks substantial number of aberrations
  • Requires specialized trained technicians or cytogeneticists

FISH

  • Targeted assay
  • Does not provide whole genome coverage
  • Numerous independent assays needed for assessment of multiple aberrations, evoking complexity, and added costs

Microarray

  • Cannot detect critical classes of aberrations implicated in disease
  • Cannot detect balanced translocations and inversions
  • Cannot resolve orientation and location of duplicated segments
  • Low sensitivity for low-level mosaicism
  • Cannot detect repeat expansions
Optical genome mapping (OGM) can detect all classes of chromosomal aberrations in a single, genome-wide workflow that karyotyping, FISH, and microarrays can assess but with 10,000x higher resolution than karyotyping can provide. Additionally, OGM can reveal structural variants (SVs) excluded by current methods, increasing pathogenic findings in both genetic disease and cancer.
  • Genome-wide coverage
  • Higher resolution (10,000x higher than karyotyping)
  • Detects all classes of structural variants in a single assay
  • Increases pathogenic findings in both genetic disease and cancer
  • Digital and automated analysis and calling of variants
  • No cell culture required
  • Detect all chromosomal abnormality classes detected by karyotyping, FISH, and Chromosomal Microarrays (CMAs)
  • Generate results that are highly concordant with standard methods, as proven by multiple peer-reviewed studies
  • Achieve 10,000x higher resolution than karyotyping with less subjective results

 

  • Unveil significantly more pathogenic aberrations than classical cytogenetics using a higher-resolution, genome-wide, and unbiased method
  • Enable more pathogenic findings, resolve cryptic cases, and determine complex events like chromothripsis with much higher precision and resolution
  • Increase the number of cases with positive results, and reduce the rate of cases labeled “normal” due to lack of findings via classical methods
  • Transform your lab workflow by reducing complexity and number of assays, eliminating the need for cell culture, and digitizing result analysis
  • Implement a streamlined end-to-end workflow with multiple automated steps for minimal hands-on time and increased efficiency
  • Leverage sophisticated software solutions to call variants, and to visualize, interpret, and report results

Case Studies

Learn how OGM has simplified and transformed lab workflows, empowering cytogenetic labs to be more efficient while increasing pathogenic findings and the number of informed cases.
Read More

“30% of previously unsolved cases for B-ALL, which previously underwent karyotype + FISH + microarray + NGS, were solved using OGM.”

Dr. Gordana Raca
Children’s Hospital Los Angeles, USA

“The combination of OGM and a targeted NGS panel for genome profiling of myeloid cancer is more cost effective than 60x whole-genome sequencing and provides the most comprehensive genome analysis.”

Dr. Ravindra Kolhe
Augusta University Georgia, USA

“OGM reveals more of what matters: more clinically relevant SVs leading to higher success rates and resolution of unsolved cases.”

Dr. Laïla El-Khattabi
Hôpitaux de Paris, (AP-HP) -Université de Paris, Paris, France

DATA EXAMPLES

Reveal all chromosomal aberrations commonly detected by classical cytogenetics while significantly increasing pathogenic findings with a simpler workflow.

Multiple studies at renowned institutions worldwide show the same outcomes. OGM not only has a high correlation to results from traditional methods but also reveals additional actionable pathogenic abnormalities.1-8

European multi-site consortium, aimed at evaluating OGM’s performance as compared to classical methods (microarray and karyotyping), across 85 constitutional samples. Nearly 100 chromosomal aberrations were evaluated, many mapping to complex regions of the human genome, and involved in repeat-mediated microdeletion/microduplication syndromes.

Institutions involved:

  • University of Oulu, Finland
  • University Hospital of Clermont-Ferrand, France
  • Université de Paris, France
  • Hospices Civils de Lyon, France
  • Saint-Joseph University, Lebanon

Author’s Conclusion:

“These results highlight the potential for OGM to provide a cost-effective and easy-to-use alternative that would allow comprehensive detection of chromosomal aberrations and structural variants, which could give rise to an era of “next-generation cytogenetics.”

OGM was proven to detect multiple categories of SVs with 100% concordance compared to classical methods.

American multi-center, double-blinded study, aimed to evaluate OGM’s performance, as compared to classical methods (karyotyping, microarray, and FISH), across 331 constitutional samples.

Institutions involved:

  • University of Rochester Medical Center, Rochester, NY, USA
  • Medical College of Wisconsin, Milwaukee, WI, USA
  • Columbia University Medical Center, New York, NY, USA
  • Greenwood Genetic Center, Greenwood, SC, USA
  • Medical College of Georgia, Augusta University, Augusta, GA, USA
  • Praxis Genomics, Atlanta, GA, USA
  • University of Iowa Health Clinics, Iowa, IA, USA

Outstanding performance for OGM across all types of SVs evaluated.

OGM was proven to not only achieve 100% concordance with classical cytogenetic methods, but also to unveil new pathogenic aberrations in 46% of a total of 94 amniocentesis samples evaluated.

Author’s statement:

“We report the feasibility and relative ease of implementing OGM for prenatal assessment compared to classical methods with the platform, demonstrating high robust technical and analytical performance and recommend OGM as a first-tier assay in prenatal settings.”

Large-scale study shows 100% concordance between OGM and cytogenetics in prenatal cohort with additional findings.

Discover How OGM Benefits Cytogenomics Studies

Learn how OGM meets the challenges of new blood cancer classifications.

Featuring Dr. Adam Smith, University Health Network, Toronto, Ontario, Canada

Watch On-demand

Hear perspectives from a pathologist and an oncologist on the utility of OGM for evaluation of myelodysplastic syndromes.

Featuring Dr. Rashmi Kanagal-Shamanna and Dr. Guillermo Garcia-Manero, MD Anderson Cancer Center

Watch On-demand

Learn More About OGM

Read about what structural variations are and why they matter.

Learn More

See how OGM reveals structural variation in a way that has never been done before.

Learn More

Find the latest research in our Publications Library.

Learn More

Sign up to receive the latest research on OGM for cytogenomic applications.

Sign Me Up!

RELATED MATERIALS

Title Source Authors
Optical genome mapping unveils hidden structural variants in neurodevelopmental disorders Nature
May 16, 2024 		Isabelle Schrauwen, Yasmin Rajendran, Anushree Acharya, et al.
A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping Blood Cancer Journal
May 3, 2024 		Ying S. Zou, Melanie Klausner, Jen Ghabrial, et al.
Generation of three isogenic, gene-edited iPSC lines carrying the APOE-Christchurch mutation into the three common APOE variants: APOE2Ch, APOE3Ch and APOE4Ch
May 2, 2024 		Mansour Haidar, Benjamin Schmid, Agustín Ruiz, et al.
Video
21:20

New features: VIA 7.1, Access 1.8.2, and Solve 3.8.2

Watch Now
Video
39:11

Introduction to VIA Software Features for OGM Analysis

Watch Now
Video
45:10

Improved Paradigm for Hematological Malignancy VIA Optical Genome Mapping

Watch Now
Literature

Purigen TBL Isolation WBC from Whole Blood

View
Literature

Macrodissection of FFPE Tissue for Nucleic Acid Purification

Ionic
View
Literature

Ionic Workflow Flyer

Ionic
View

Related Focus Areas & Applications

Solid Tumors

Learn More

Hematological Malignancies

Learn More

Genetic Diseases

Learn More

Related Products

Sample Preparation Kits

Learn More

Saphyr® System

Learn More

VIA™ Analysis Software 

Learn More
References:
  1. Neveling K, Mantere T, Vermeulen S, et al. Next-generation cytogenetics: Comprehensive assessment of 52 hematological malignancy genomes by optical genome mapping. Am J Hum Genet. 2021;108(8):1423-1435. doi:10.1016/j.ajhg.2021.06.001
  2. Levy B, Baughn LB, Chartrand S, et. al. A national multicenter evaluation of the clinical utility of optical genome mapping for assessment of genomic aberrations in acute myeloid leukemia. Preprint. Posted online November 10, 2020, medRxiv. doi: 10.1101/2020.11.07.20227728
  3. Lestringant V, Duployez N, Penther D, et al. Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias. Genes Chromosomes Cancer. 2021;60(10):657-667. doi:10.1002/gcc.22971
  4. Stinnett V, Jiang L, Haley L, et al. Adoption of optical genome mapping in clinical cancer cytogenetic laboratory: A stepwise approach. Cancer Genetics. 2022;260-261:3. doi:10.1016/j.cancergen.2021.05.021
  5. Kriegova E, Fillerova R, Minarik J, et al. Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. Sci Rep. 2021;11(1):14671. Published 2021 Jul 19. doi:10.1038/s41598-021-93835-z
  6. Sahajpal NS, Mondal AK, Tvrdik T, et al. Clinical validation and diagnostic utility of optical genome mapping for enhanced cytogenomic analysis of hematological neoplasms. The Journal of Molecular Diagnostics. 2022. doi:10.1016/j.jmoldx.2022.09.009
  7. Lühmann JL, Stelter M, Wolter M, et al. The clinical utility of optical genome mapping for the assessment of genomic aberrations in acute lymphoblastic leukemia. Cancers (Basel). 2021;13(17):4388. Published 2021 Aug 30. doi:10.3390/cancers13174388
  8. Yang H, Garcia-Manero G, Sasaki K, et al. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia. 2022;36(9):2306-2316. doi:10.1038/s41375-022-01652-8
  9. Mantere T, Neveling K, Pebrel-Richard C, et al. Optical genome mapping enables constitutional chromosomal aberration detection. Am J Hum Genet. 2021;108(8):1409-1422. doi:10.1016/j.ajhg.2021.05.012
  10. Iqbal MA, Broeckel U, Levy B, et al. Multi-site technical performance and concordance of optical genome mapping: Constitutional postnatal study for SV, CNV, and repeat array analysis. Preprint. Posted online December 27, 2021. medRxiv. doi: https://doi.org/10.1101/2021.12.27.21268432
  11. Sahajpal N, Mondal AK, Fee T, et al. Clinical validation and diagnostic utility of optical genome mapping in prenatal diagnostic testing. Preprint. Posted online May 11, 2022. medRxiv.  doi: https://doi.org/10.1101/2022.05.11.22274975